A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 13 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 13 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
- 02 Nov 2015 New trial record